Eurican L

País: Irlanda

Idioma: inglés

Fuente: HPRA (Health Products Regulatory Authority)

Ingredientes activos:

Inactivated leptospira canicola; Inactivated leptospira icterohaemorrhagiae

Disponible desde:

Boehringer Ingelheim Vetmedica GmbH

Código ATC:

QI07AB01

Designación común internacional (DCI):

Inactivated leptospira canicola; Inactivated leptospira icterohaemorrhagiae

Dosis:

.

formulario farmacéutico:

Suspension for injection

tipo de receta:

POM: Prescription Only Medicine as defined in relevant national legislation

Área terapéutica:

leptospira

Estado de Autorización:

Authorised

Fecha de autorización:

2004-11-05

Ficha técnica

Health Products Regulatory Authority
29 May 2020
CRN009PHD
Page 1 of 4
SUMMARY OF PRODUCT CHARACTERISTICS
1 NAME OF THE VETERINARY MEDICINAL PRODUCT
Eurican L
2 QUALITATIVE AND QUANTITATIVE COMPOSITION
Inactivated_ Leptospira canicola................................. _} >
80% protection*
Inactivated_ Leptospira icterohaemorrhagiae............. _}
Excipient.....................................................................
qs 1 dose of 1 ml
*According to Ph. Eur. hamster potency test
For a full list of excipients, see section 6.1.
3 PHARMACEUTICAL FORM
Suspension for injection.
4 CLINICAL PARTICULARS
4.1 TARGET SPECIES
Dogs from 8 weeks of age.
4.2 INDICATIONS FOR USE, SPECIFYING THE TARGET SPECIES
In dogs:
Active immunisation against _Leptospira canicola_ and _Leptospira
icterohaemorrhagiae_ to prevent mortality and to reduce clinical
symptoms of Leptospira infections caused by these agents.
Onset of immunity: 14 days after primary vaccination.
The duration of immunity is one year.
4.3 CONTRAINDICATIONS
None.
4.4 SPECIAL WARNINGS FOR EACH TARGET SPECIES
None.
Health Products Regulatory Authority
29 May 2020
CRN009PHD
Page 2 of 4
4.5 SPECIAL PRECAUTIONS FOR USE
(I) SPECIAL PRECAUTIONS FOR USE IN ANIMALS:
Vaccinate only healthy animals
(II) SPECIAL PRECAUTIONS TO BE TAKEN BY THE PERSON ADMINISTERING THE
MEDICINAL PRODUCT TO THE ANIMALS:
In the case of accidental self-injection, wash the area immediately
with water.
4.6 ADVERSE REACTIONS (FREQUENCY AND SERIOUSNESS)
In rare cases, immediately after injection, transient pain may occur
at the injection site. A temperature increase of
approximately 1°C lasting no more than a day, may occur in rare
cases.
In rare circumstances, a hypersensitivity reaction may occur, which
may require appropriate symptomatic treatment.
4.7 USE DURING PREGNANCY, LACTATION OR LAY
In the absence of data from studies in seronegative bitches, the
vaccine should only be used in pregnant bitches which have
been vaccinated before pregnancy.
4.8 INTERACTION WITH OTHER MEDICINAL PRODUCTS AND OTH